China Pharma Holdings Free Cash Flow (FCF) History (CPHI)
China Pharma Holdings reported $88,937 in free cash flow for fiscal 2025, an increase of $533,411 from the previous fiscal year, with a free cash flow margin of 2.15%.
View full China Pharma Holdings company overviewChina Pharma Holdings free cash flow by year
| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2025 | 2025-12-31 | $88,937 | $533,411 | — | +2.15% |
| 2024 | 2024-12-31 | −$444,474 | $266,729 | — | −9.81% |
| 2023 | 2023-12-31 | −$711,203 | $100,306 | — | −10.14% |
| 2022 | 2022-12-31 | −$811,509 | −$123,616 | — | −10.01% |
| 2021 | 2021-12-31 | −$687,893 | $221,674 | — | −7.13% |
| 2020 | 2020-12-31 | −$909,567 | −$1.4M | — | −8.37% |
| 2019 | 2019-12-31 | $472,309 | −$1.4M | −74.20% | +4.32% |
| 2018 | 2018-12-31 | $1.8M | $1.1M | +159.81% | +14.85% |
| 2017 | 2017-12-31 | $704,737 | −$2.0M | −73.92% | +5.33% |
| 2016 | 2016-12-31 | $2.7M | $37,546 | +1.41% | +17.36% |
| 2015 | 2015-12-31 | $2.7M | $1.6M | +160.16% | +13.09% |
| 2014 | 2014-12-31 | $1.0M | $11.2M | — | +4.63% |
| 2013 | 2013-12-31 | −$10.2M | −$13.7M | — | −31.09% |
| 2012 | 2012-12-31 | $3.5M | −$1.4M | −28.62% | +6.40% |
| 2011 | 2011-12-31 | $4.9M | −$2.8M | −36.74% | +6.02% |
| 2010 | 2010-12-31 | $7.7M | — | — | +10.38% |
China Pharma Holdings quarterly free cash flow
| Fiscal quarter | Period ended | Free cash flow | Change | YoY growth | FCF margin |
|---|---|---|---|---|---|
| Q4 2025 | 2025-12-31 | $151,536 | $125,615 | +484.61% | +12.36% |
| Q3 2025 | 2025-09-30 | −$204,971 | −$148,799 | — | −27.10% |
| Q2 2025 | 2025-06-30 | $274,242 | — | — | +26.74% |
| Q1 2025 | 2025-03-31 | −$132,000 | — | — | −11.62% |
| Q4 2024 | 2024-12-31 | $25,921 | — | — | +2.29% |
| Q3 2024 | 2024-09-30 | −$56,172 | — | — | −5.11% |
| Q4 2022 | 2022-12-31 | $557,326 | — | — | +19.08% |
| Q3 2022 | 2022-09-30 | −$33,427 | $833,396 | — | −1.70% |
| Q2 2022 | 2022-06-30 | −$509,114 | — | — | −31.56% |
| Q1 2022 | 2022-03-31 | −$880,830 | — | — | −54.91% |
| Q3 2021 | 2021-09-30 | −$866,823 | −$383,006 | — | −43.81% |
| Q4 2020 | 2020-12-31 | $102,297 | $174,663 | — | +3.49% |
| Q3 2020 | 2020-09-30 | −$483,817 | −$951,856 | — | −20.15% |
| Q2 2020 | 2020-06-30 | −$401,239 | −$787,545 | — | −10.64% |
| Q1 2020 | 2020-03-31 | −$591,950 | −$281,624 | — | −33.56% |
| Q4 2019 | 2019-12-31 | −$72,366 | −$928,985 | — | −2.37% |
| Q3 2019 | 2019-09-30 | $468,039 | −$411,900 | −46.81% | +19.69% |
| Q2 2019 | 2019-06-30 | $386,306 | $812,001 | — | +15.03% |
| Q1 2019 | 2019-03-31 | −$310,326 | −$830,438 | — | −10.59% |
| Q4 2018 | 2018-12-31 | $856,619 | −$10,989 | −1.27% | +26.42% |
| Q3 2018 | 2018-09-30 | $879,939 | $217,424 | +32.82% | +38.28% |
| Q2 2018 | 2018-06-30 | −$425,695 | $382,827 | — | −13.41% |
| Q1 2018 | 2018-03-31 | $520,112 | $536,976 | — | +14.38% |
| Q4 2017 | 2017-12-31 | $867,608 | −$499,331 | −36.53% | +22.55% |
| Q3 2017 | 2017-09-30 | $662,515 | −$184,184 | −21.75% | +20.95% |
| Q2 2017 | 2017-06-30 | −$808,522 | −$33,234 | — | −27.72% |
| Q1 2017 | 2017-03-31 | −$16,864 | −$1.3M | — | −0.51% |
| Q4 2016 | 2016-12-31 | $1.4M | −$645,843 | −32.09% | +25.98% |
| Q3 2016 | 2016-09-30 | $846,699 | −$320,988 | −27.49% | +27.09% |
| Q2 2016 | 2016-06-30 | −$775,288 | −$214,710 | — | −21.89% |
| Q1 2016 | 2016-03-31 | $1.3M | $1.3M | — | +34.72% |
| Q4 2015 | 2015-12-31 | $2.0M | $3.6M | — | +44.69% |
| Q3 2015 | 2015-09-30 | $1.2M | $985,071 | +539.42% | +26.07% |
| Q2 2015 | 2015-06-30 | −$560,578 | −$468,227 | — | −9.88% |
| Q1 2015 | 2015-03-31 | −$49,345 | −$2.5M | — | −0.87% |
| Q4 2014 | 2014-12-31 | −$1.6M | $12.2M | — | −47.19% |
| Q3 2014 | 2014-09-30 | $182,616 | −$416,354 | −69.51% | +3.28% |
| Q2 2014 | 2014-06-30 | −$92,351 | −$3.3M | — | −1.51% |
| Q1 2014 | 2014-03-31 | $2.5M | $2.7M | — | +34.84% |
| Q4 2013 | 2013-12-31 | −$13.8M | −$14.4M | — | −164.08% |
| Q3 2013 | 2013-09-30 | $598,970 | −$462,949 | −43.60% | +7.38% |
| Q2 2013 | 2013-06-30 | $3.2M | $1.8M | +126.30% | +40.41% |
| Q1 2013 | 2013-03-31 | −$234,413 | −$627,867 | — | −2.84% |
| Q4 2012 | 2012-12-31 | $598,360 | $843,020 | — | +5.14% |
| Q3 2012 | 2012-09-30 | $1.1M | −$684,383 | −39.19% | +8.72% |
| Q2 2012 | 2012-06-30 | $1.4M | −$624,584 | −30.35% | +9.82% |
| Q1 2012 | 2012-03-31 | $393,454 | −$932,073 | −70.32% | +2.45% |
| Q4 2011 | 2011-12-31 | −$244,660 | — | — | −1.09% |
| Q3 2011 | 2011-09-30 | $1.7M | −$921,236 | −34.54% | +8.32% |
| Q2 2011 | 2011-06-30 | $2.1M | — | — | +10.50% |
| Q1 2011 | 2011-03-31 | $1.3M | — | — | +7.32% |
| Q3 2010 | 2010-09-30 | $2.7M | — | — | +14.28% |
China Pharma Holdings free cash flow growth trends
Over the last five reported fiscal years, free cash flow grew from −$909,567 to $88,937, a net increase of $998,504. China Pharma Holdings's latest reported quarter, Q4 2025, generated $151,536 in free cash flow, an increase of 484.61% year over year.
What free cash flow means
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
How free cash flow is calculated
TickerStat calculates free cash flow as reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review China Pharma Holdings source filings ↗